122 related articles for article (PubMed ID: 12070713)
1. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
Perambakam S; Xue BH; Sosman JA; Peace DJ
Cancer Immunol Immunother; 2002 Jul; 51(5):263-70. PubMed ID: 12070713
[TBL] [Abstract][Full Text] [Related]
2. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
3. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
[TBL] [Abstract][Full Text] [Related]
4. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
Xue BH; Zhang Y; Sosman JA; Peace DJ
Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
[TBL] [Abstract][Full Text] [Related]
5. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
6. CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis.
Klyushnenkova EN; Ponniah S; Rodriguez A; Kodak J; Mann DL; Langerman A; Nishimura MI; Alexander RB
J Immunother; 2004; 27(2):136-46. PubMed ID: 14770085
[TBL] [Abstract][Full Text] [Related]
7. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
[TBL] [Abstract][Full Text] [Related]
9. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
[TBL] [Abstract][Full Text] [Related]
10. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
11. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
Elkord E; Williams PE; Kynaston H; Rowbottom AW
Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
[TBL] [Abstract][Full Text] [Related]
13. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient.
Harada M; Matsueda S; Yao A; Noguchi M; Itoh K
J Immunother; 2005; 28(4):368-75. PubMed ID: 16000955
[TBL] [Abstract][Full Text] [Related]
15. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
[TBL] [Abstract][Full Text] [Related]
16. Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes.
O'Beirne J; Farzaneh F; Harrison PM
J Exp Clin Cancer Res; 2010 May; 29(1):48. PubMed ID: 20465843
[TBL] [Abstract][Full Text] [Related]
17. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
[TBL] [Abstract][Full Text] [Related]
18. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
[TBL] [Abstract][Full Text] [Related]
19. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
[TBL] [Abstract][Full Text] [Related]
20. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
